4 Международный Семинар по Пресепсину,
Токио 14 сентября 2018 г.
TOKYO BAYПрограмма
OPENING REMARKS: Masahide Kawamura, LSI Medience Corporation
Session 1: Mechanisms
Chairman: Masatoshi Wakui, Keio University School of Medicine, Japan
1. Phagocytosis model of presepsin production mechanisms
Kamon Shirakawa, LSI Medience Corporation, Japan
2. In vitro presepsin releasing assay reveals the difference of presepsin levels in response to various species of
bacteria
Yusuke Koizumi, Aichi Medical University Hospital, Japan
3. Increased presepsin levels are associated with the severity of fungal bloodstream infections
Yuuki Bamba, Niigata University Graduate School of Medical and Dental Sciences, Japan
Session 2: New Insight of Presepsin
Chairman: Ralf Thomae, Mitsubishi Chemical Europe
1. Update international Presepsin clinical studies in EU
Ralf Thomae, Mitsubishi Chemical Europe, Duesseldorf, Germany
2. Clinical significance of presepsin in patients with systemic lupus erythematosus
Yuichiro Fujieda , Hokkaido University Hospital, Japan
3. Cerebrospinal Fluid Presepsin As a Marker of Nosocomial Infections of the Central Nervous System
Konstantin Popugaev, Burnazian State Scientific Center of Federal Biomedical Agency of Russia, Moscow,
Russia
Session 3: Emergency and Intensive care I (including NICU)
Chairman:Hiroyasu Ishikura, Fukuoka University Hospital
1. A study of presepsin in the new sepsis guideline
Gaku Takahashi, Iwate Medical University , Japan
2. Presepsin as a predictor of positive blood culture among newborns suspected sepsis
Yukihide Miyosawa, Shinshu University, Japan
3. Early Differential Value of Plasma Presepsin in Infection of Trauma Patient
Li Chunsheng, Professor and Chief scientific consultant in Emergency Medicine, Beijing Chaoyang Hospital/
Beijing Friendship Hospital, Capital Medical University, China
Session 4: Emergency and Intensive care II
Chairman:Toshiaki Ikeda, Tokyo Medical University Hachioji Medical Center
1. Comparison of presepsin and other sepsis biomarkers in patients after major surgery with and without
Immunosuppression
Antonin Jabor, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech
2. Presepsin Usage in Monitoring Septic Patients in Emergency Room and as a Guide to Antimicrobial Therapy
in Cardiac Surgery
Pejakovic and Karan (presented by Marija Jerosimovic, ALURAmed, Serbia) Clinical Center of Serbia,
Clinical Center of Vojvodina and Dedinje Cardiovascular Institute, Belgrade,Serbia
3. The relationship of presepsin in patients with severe acute pancreatitis
Katsuya Kitamura, Showa University School of Medicine, Japan
Session 5: Prognosis
Chairman: Somsak Lolekha, Professor Emeritus of the Royal College of
Pediatricians, Former President, the Medical Council, and Pediatric Society of Thailand
1. The role of presepsin and immunologic biomarkers in prediction outcome of severe sepsis patients
Nattachai Srisawat, Clinical Instructor, Department of Medicine, Faculty of Medicine, Chulalongkorn
University, Bangkok, Thailand
2. Prognostic Utility of Presepsin in Critical Care
Mina Hur, Department of Laboratory Medicine, Konkuk University Medical Center, Konkuk University
School of Medicine, Korea
CLOSING REMARKS Takashi Kurihara, LSI Medience Corporation